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Background: Rapid wound healing of oral soft tissue may reduce the opportunity of infection and discomfort of
patients. Previous studies have demonstrated that enhancement of angiogenesis is an effective way to accelerate
wound repair. In this study, to enhance angiogenesis and healing of palatal wounds, dimethyloxalylglycine (DMOG)
was applied to a rat palatal wound model. DMOG is known to inhibit oxygen-dependent degradation of hypoxia
inducible factor-1 alpha (HIF-1α), which can lead to up-regulation of angiogenesis markers, favoring wound repair. We
also evaluated the effects of DMOG on cell migration and HIF-1α expression of rat palatal (RP) cells. Furthermore, mRNA
and protein expression of vascular endothelial growth factor (VEGF) were analyzed in DMOG-treated RP cells.
Methods: Primary cultures of rat palatal (RP) cells were obtained from Sprague–Dawley (SD) rats. Effects of DMOG on
cell viability and migration of RP cells were evaluated by using a formazan and culture insert, respectively. VEGF mRNA
was observed by real-time PCR, and VEGF and HIF-1α proteins were detected by Western blotting. For the animal study,
excisional wounds, 3 mm in diameter, were made at the central part of the palate of SD rats. DMOG with hyaluronic
acid ointment was topically applied three times during 1 week, and then wound closures were quantitated
photographically and histologically.
Results: DMOG was cytotoxic to RP cells at concentrations higher than 2 mM and did not affect cell migration at non-
cytotoxic concentrations. mRNA and protein expression of VEGF were significantly stimulated by DMOG treatment. The
protein level of HIF-1α was also stabilized in RP cells by DMOG. In the animal study, groups treated with 1 mg/ml
DMOG showed an increase of rat palatal wound contractures.
Conclusions: DMOG enhanced wound healing of rat palatal mucosa, which was likely due to the angiogenic effect of
the agent.
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Wound healingBackground
Oral soft tissues are inevitably damaged during auto-
genous gingival grafting, periodontal surgery, or dental
implant surgery. Recovery of soft tissue from injuries de-
pends on wound size, location, condition of oral hygiene,
and the level of immunity. Oral administration or topical
application of antibiotics is recommended as a choice of
oral wound care to prevent bacterial infection. In the
case of large-sized defects that can be caused by au-
togenous gingival grafts, dressing materials are used to
protect damaged donor sites and to help the wound* Correspondence: yanghc@snu.ac.kr
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unless otherwise stated.healing process. Intended rapid wound healing can also
reduce the opportunity of infection and discomfort of pa-
tients. In a previous study, acceleration of palatal mucosa
repair was achieved with a collagen-gelatin scaffold retain-
ing basic fibroblast growth factor (bFGF), a potent angio-
genesis inducer [1]. Thymosin β4 (Tβ4), an oligopeptide
that can sequester G-actin monomers, also promotes
wound healing of rat mucosa [2]. Enhancement of cell mi-
gration and angiogenesis is likely to be involved in wound
healing by Tβ4. Umeki et al. have shown that wound heal-
ing of oral mucosa is accelerated by leptin, a circulating
anti-obesity hormone, via enhancement of angiogenesis
[3]. These studies imply that enhancement of angiogenesis
is an effective way to accelerate oral wound repair.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tors such as fibroblast growth factor (FGF) [4], vascular
endothelial growth factor (VEFG) [5], platelet-derived
growth factor (PDGF) [6, 7], and transforming growth
factor β (TGF-β) [8, 9]. Several peptides have also been
reported to promote angiogenesis [10–12]. Considering
the importance of angiogenesis in wound healing, the
application of angiogenic proteins and peptides to wounds
is expected to expedite the repair of oral tissue damage if
the molecules are properly delivered to the wound sites.
However, the stability and activity of proteins and pep-
tides cannot be assured in the oral environment where
temperature and pH are changeable due to eating and
drinking. Instead, angiogenic small molecules which are
chemically stable can be more appropriate for the harsh
conditions of the oral cavity.
Dimethyloxalylglycine (DMOG), with small molecular
weight, is a cell-permeable unspecific inhibitor of prolyl
hydroxylases (PHDs) [13]. Under normoxic conditions,
PHD2 is known to hydroxylate specific proline residues
in HIF-1α, which then leads to degradation of HIF-1α by
the ubiquitin-proteasome pathway [14–16]. Therefore,
inhibition of PHD2 by DMOG can prevent HIF-1α deg-
radation, creating an environment similar to that found
in hypoxic cells. Furthermore, various genes related to
tissue repair such as angiogenesis are upregulated. A
previous study showed that DMOG enhanced the pro-
duction of VEGF in periodontal fibroblast cells [17]. Fur-
thermore, Botusan et al. demonstrated that DMOG
stabilizes HIF-1α and enhances dermal wound healing in
diabetic mice [18]. In this study, the effect of DMOG on
oral wound healing was investigated in a rat palatal
wound model. We also evaluated the effects of DMOG
on cell migration and HIF-1α expression of rat palatal
(RP) cells. Furthermore, mRNA and protein expression
of vascular endothelial growth factor (VEGF) were ana-
lyzed in DMOG-treated RP cells.
Methods
Chemical reagents and cell culture
Cell culture medium and antibiotics were purchased from
WELGENE Inc. (Daegu, Korea). Fetal bovine serum (FBS)
was purchased from Lonza (Basel, Switzerland), and other
experimental reagents were obtained from Sigma-Aldrich
Co. (Saint Louis, MO, USA), unless otherwise specified.
RP cells were isolated from the palatal tissues of 5-
week old male Sprague–Dawley (SD) rats. Isolated pal-
atal tissues were washed with phosphate buffered saline
(PBS) (PH 7.4), aseptically minced into pieces, and then
immersed in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% FBS and antibiotic solution
(100 U/ml of penicillin-G and 100 μg/ml of strepto-
mycin) at 37 °C in a humidified incubator (5% CO2/95%
air). After 20 days of culture with medium changes at3-day intervals, RP cells were collected and sub-cultured
under the same conditions. Passages three through five
were used for this study. Although we did not identify the
type of palatal cells at the molecular level, morphological
features of the isolated cells under the microscope indi-
cated distinct dominance of fibroblast-like cells.
Cytotoxicity
RP cells incubated until 80% confluent were removed
and sub-cultured at 0.8 × 105 cells per ml in 96-well
plates and incubated at 37 °C with 5% CO2 in air for
24 h, and then the cells were treated with DMOG at
various concentrations ranging from 0.1 to 10 mM.
After treatment for 24 h, the cell viabilities were quanti-
fied using the Cell Counting Kit-8 (WST-8) (Dojindo La-
boratories, Kumamoto, Japan). Cells were incubated in
100 μl of WST-8 solution for 1 h at 37 °C in a humidi-
fied atmosphere (5% CO2/95% air). The absorbance was
measured at a wavelength of 450 nm using a plate reader
(Sunrise, TECAN, Salzburg, Austria). The optical density
of untreated cells was designated as 100%, and cell via-
bility of treated cells was expressed as the percentage of
untreated negative control.
Cell migration assay
For the in vitro cell migration assay, a culture insert
(ibidi GmbH, Martinsried, Germany) was used to create
a wound in cell culture. The culture insert was placed
on a culture dish, and 70 μl of RP cell suspension (5 ×
105 cells/ml) was added into both wells of the insert.
The RP cells were incubated at 37 °C for 48 h and then
exposed to DMOG (0, 0.1, 0.5, 1, 2 mM) in culture
media containing 2% FBS for the cell migration analysis.
Wound closure was observed and recorded at intervals
under a phase contrast microscope (Olympus, Tokyo,
Japan). To quantify cell migration, the uncovered area
where no cells were present was measured by using Ima-
geJ program, and the ratio of uncovered area between
untreated control and treated groups was obtained.
mRNA expression analysis by real-time PCR
The effect of DMOG on the expression of VEGF mRNA
was investigated by real-time polymerase chain reaction
(RT-PCR) assay. After treatment with DMOG at 0, 0.1,
0.5, 1, and 2 mM for 24 h, total RNA was isolated using
RNA extraction reagent (WelPrep Total RNA Isolation
Reagent, WELGENE Inc.). From the total RNA, cDNA
was prepared using a cDNA synthesis kit (Power cDNA
Synthesis Kit, iNtRON Biotechnology, Sungnam, Korea),
and RT-PCR was performed in an ABI PRISM 7500 Se-
quence Detection System Thermal Cycler (Applied Bio-
systems, Foster City, CA, USA) with 20 μl reaction
volumes containing 10 μl SYBR premix Ex Taq (Takara
Bio, Otsu, Japan), 0.4 μl ROX Reference Dye II (Takara
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cation were as follows: VEGF sense, 5’-GAGTATATC
TTCAAGCCGTCCTGT-3’; VEGF antisense, 5’-ATCTG
CATAGTGACGTTGCTCTC-3’; GAPDH (Glyceralde-
hyde-3-phosphate dehydrogenase) sense, 5’-TGTGTCC
GTCGTGGATCTGA-3’; GAPDH antisense, 5’-CCTGC
TTCACCACCTTCTTGAT-3’. The PCR conditions were
95 °C for 30 s, followed by 40 cycles of denaturation at
95 °C for 5 s and annealing at 63 °C (34 s) for VEGF. All
reactions were run in triplicate. Gene expression was
evaluated on the basis of the threshold cycle (CT value)
and normalized to the expression of the GAPDH gene.
Western blot analysis
Western blot analysis was performed to examine the
protein expression of HIF-1α and VEGF in DMOG-
treated palatal cells. After treatment with DMOG at
various concentrations for 24 h, cells were lysed in ex-
traction buffer containing 50 mM Tris base-HCl (PH
7.5), 150 mM NaCl, 0.5% Triton-X 100, and one tablet
of protease inhibitor cocktail (1 tablet/10 ml, Roche Ap-
plied Science, Mannheim, Germany) for 45 min on ice.
Extracts containing equal amounts of protein were run
on 10% sodium dodecyl sulfate polyacrylamide gels and
transferred to polyvinylidene difluoride membranes. The
blots were incubated with rabbit polyclonal antibodies
against VEGF, HIF-1α, or GAPDH in PBST (PBS con-
taining 0.1% Tween 20) for 1.5 h, washed three times
with PBST, and then probed with goat anti-rabbit sec-
ondary antibodies conjugated to horseradish peroxidase.
The protein bands were visualized using a chemilumin-
escence kit (WEST-ZOL plus Western Blot Detection
System, iNtRON Biotechnology). Chemiluminescence
was detected using the LAS 1000 Plus Luminescent
Image Analyzer (Fuji Photo Film, Tokyo, Japan). All anti-
bodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA).
Rat palatal wound healing assay
After confirming the angiogenesis effect of DMOG on
RP cells, the effect of DMOG on wound healing of pal-
atal tissue was performed in a rat palatal wound model.
All rats were housed under specific pathogen-free (SPF)
conditions at the animal experimental center of Seoul
National University Dental School. Eighteen 13-week-
old male SD rats (six rats for each group), weighing
300–350 g, were used in the present study. All animal
experiments were approved by the Institutional Animal
Care and Use Committee (SNU-130123-8-1) of Seoul
National University (Seoul, Korea). Under general anes-
thesia, punch wounds were made on a central area of hard
palate with a disposable 3-mm diameter biopsy punch
(Kai Industries Ltd., Gifu, Japan), exposing a circular area
of bare bone. Hyaluronic acid (HA) ointment (20 mg/ml)containing 0, 0.5, or 1 mg/ml (5.7 mM) DMOG was ap-
plied to the wound area. After the surgery, animals were
fed a standard diet of pellets and water with enrofloxacin.
The agents were re-applied on days 2 and 4 under
anesthesia to reduce stress, and the rats were sacrificed on
day 7. The hard palate was separated, and the wound area
was observed with a stereoscopic microscope (Nikon,
Tokyo, Japan) and by histological analysis. The wound
area on the microscopic images was calculated using Cell-
Sense Dimension 1.6 software (Olympus, Tokyo, Japan).
Palatal specimens were taken for histomorphometric
evaluation and samples were stained with haematoxylin
and eosin (H&E) staining. More than ten slides for each
sample were prepared, and we selected a section that
exhibited the widest diameter of wound for histological
analysis. The sections were examined under a light micro-
scope (Olympus), and the distance of wound margins in
each section was measured with a calibrated ocular
micrometer.
Statistical analysis
For statistical analysis, each experiment was performed in
triplicate unless otherwise specified. The data are ex-
pressed as the mean ± Standard Deviation. Statistical ana-
lyses were determined by one-way ANOVA for in vivo
study and cell migration assay. The unpaired Student’s
t-test was used for the other in vitro results. A P-value
< 0.05 was considered statistically significant.
Results
Cell viability and migration of DMOG-treated rat palatal
cells
To investigate the effects of DMOG on cell viability, rat
palatal cells were exposed to DMOG for 24 h. The cyto-
toxicity of DMOG was demonstrated at concentrations
higher than 2 mM. Cell viability was reduced to 60% at
4 mM, and was mostly impaired at 8 mM (Fig. 1). Cell
migration was observed in culture media containing 2%
FBS to attenuate cell motility. In the absence of FBS, un-
treated palatal cells did not display any movement dur-
ing 48 h (data not shown). In 2% FBS medium, a slight
movement of cells was shown at 12 h, and about a half
of the void area was filled with penetrated cells at 48 h.
Cell migration during 48 h was not affected by DMOG
at non-cytotoxic concentrations (0–2 mM) (Fig. 2).
mRNA and protein expression of the VEGF gene and
HIF-1α protein levels in DMOG-treated cells
mRNA and protein expression of VEGF was quantified
to investigate the effects of DMOG on angiogenesis at
the molecular level. As shown in Fig. 3A, DMOG en-
hanced gene expression of VEGF dose-dependently in
RP cells. Treatment with DMOG at 0.5 mM showed an
increase in the amount of VEGF mRNA that was
Fig 1 Effect of DMOG on the viability of RP cells. RP cells were treated
with DMOG at concentrations ranging from 0 to 10 mM for 24 h. Data
and error bars indicate means ± SD of three independent experiments.
*demonstrates a statistically significant (P < 0.05) difference between
control and treated cells
Fig 2 Cell migration of DMOG-treated RP cells. (A) Representative photom
at different concentrations in culture media containing 2% FBS for the cell
migration. Cell migration was quantified by calculating the ratio between a ce
significant differences appeared among all groups at the same time point (P <
Zhu et al. BMC Oral Health  (2015) 15:60 Page 4 of 8significantly higher than that of the control group, and
2 mM DMOG caused a 2.3-fold increase in mRNA
levels (Fig. 3A). The protein expression of VEGF was
also up-regulated by DMOG at concentrations higher
than 0.5 mM. Unlike the dose-dependent pattern of
mRNA expression in DMOG-treated cells, a 3.4-fold
higher level of protein was maintained at DMOG con-
centrations between 0.5 and 2 mM (Fig. 3B).
The stability of HIF-1α protein in RP cells was also af-
fected by DMOG. Greater amounts of HIF-1α protein
were detected in cells treated with DMOG even at
0.1 mM which did not cause a change in the protein
level of VEGF (Fig. 3B). A 2.6-fold increase in HIF-1α
protein levels was shown in cells that were treated withicrographs of a cell migration assay. RP cells were treated with DMOG
migration assay with 40X magnification. (B) Quantitative analysis of cell
ll-free and cell-occupied area inside the wound space. No statistically
0.05)
Fig 3 mRNA expression of the VEGF gene and protein expression of VEGF and HIF-1α in DMOG-treated cells. RP cells were treated with DMOG at
concentrations ranging from 0 to 2 mM for 24 h. Data and error bars indicate means ± SD of three independent experiments. *demonstrates
mRNA (A) and protein (B) expression levels that are significantly different from those of untreated control cells (P < 0.05)
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tein levels was shown at higher concentrations, indicat-
ing that 0.5 mM of DMOG is enough to stabilize the
entire amount of HIF-1α protein in cells.The effects of DMOG on palatal wound healing in rats
In a rat palatal wound model, DMOG was applied at
two concentrations: 0.5 and 1 mg/ml. The DMOG-
treated group did not show any symptoms of physio-
logical abnormality during the experimental period. As
shown in Fig. 4A, the wound area was not completely
epithelized at 1 week, and was readily distinguished
from undamaged intact tissue that was pale pink in
color. The average area of the wound surface in the
control group was 2.4 mm2. In the test group treated
with DMOG at 1 mg/ml, the wound area was reduced
to 1.8 mm2, which is modest but still a statisticallysignificant decrease. At 0.5 mg/ml, DMOG did not
affect wound closure.
To confirm the results shown in Fig. 4A, the max-
imum distance of the unepithelized region (distance of
wound margin) was measured in histological sections
of the wound area. The distance was also reduced in
rats that were treated with 1 mg/ml DMOG, while there
was no statistically significant difference in the distance of
the wound margin between control and 0.5 mg/ml
DMOG-treated groups (Fig. 5). Therefore, DMOG clearly
accelerated palatal wound healing in rats at a certain
concentration.
Discussion
HIF prolyl hydroxylase inhibitors have been investi-
gated to find a new drug for treatment of anemia, kid-
ney disease, and heart failure [19, 20]. Promotion of
angiogenesis is a targeted therapeutic effect of the
Fig 4 Effects of DMOG on healing of palatal wounds. (A) Stereoscopic microscope images of palatal wounds 1 week after surgery. DMOG was
topically applied to test groups (b1–b6: 0.5 mg/ml, c1–c6: 1 mg/ml), and vehicle (20 mg/ml HA) was applied to control groups (a1–a6) (Scale bar:
1 mm). (B) Wound area calculated from the stereoscopic microscope images. *indicates a significant difference in the palatal wound area
compared to that of the untreated control groups (P <0.05)
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evitably necessary step in tissue regeneration or wound
healing.
We observed the effect of DMOG, a HIF-1α prolyl hy-
droxylase inhibitor, on wound healing of rat palatal mu-
cosa. For in vitro studies, cytotoxicity and the ability to
regulate VEGF and HIF-1α in cells originating from rat
palatal tissues were investigated. The cytotoxicity of
DMOG against rat palatal cells appeared at relatively
higher concentrations (Fig. 1). Accumulation of HIF-1α
protein is not likely a direct cause of cell death because
the intracellular level of HIF-1α was already saturated at
0.5 mM and was not altered until 2.0 mM. A previous
study reported cell cycle arrest by PHD inhibitors [21],
which provides a possible explanation for the toxic ef-
fects of DMOG. Since cytotoxicity undoubtedly can
disturb tissue repair, DMOG concentrations for in vivo
studies should be carefully chosen to elicit a wound
healing effect. Marchbank et al. demonstrated that
DMOG stimulates migration of human stomach and
colonic carcinoma cells [22]. However, a decrease in
single cell migration has been observed in the hypoxia
state of certain fibroblast cells [23]. Therefore, the ef-
fect of hypoxia or HIF-1α accumulation on cell migra-
tion is cell-type specific. The motility of rat palatalcells in this study was not promoted by DMOG (Fig. 2),
which suggests that migration of fibroblast-like palatal
cells was not a determining factor in wound healing of
DMOG-treated palatal cells.
Previously, it has been demonstrated that PHD inhibi-
tors up-regulate the expression of VEGF in various kinds
of cells, including endothelial cells [24], epithelial cells
[25], gingival fibroblasts, and periodontal ligaments [17].
In agreement with the results of these studies, the
present study also confirmed the ability of DMOG to
up-regulate the expression of VEGF (Fig. 3) in rat palatal
fibroblast-like cells. DMOG also induced stabilization of
HIF-1α protein, and the range of effective concentra-
tions was overlapped except for 0.1 mM at which only
HIF-1α protein but not VEGF was up-regulated. This in-
dicates that VEGF cannot be induced in the absence of
obvious increases in the amount of HIF-1α. Additionally,
the stabilization of HIF-1α is also known to induce glu-
cose transporter-1 and phosphoglycerate kinase-1, which
can improve the wound healing by enhancing the re-
epithelialization [26].
Because of the moist condition of oral cavity in the
animal experiment, it was required to employ a vehicle
to extend the residual period of a drug at the wound
area. As a vehicle for delivery of DMOG to oral mucosa
Fig 5 Histological observation. (A) Representative haematoxylin and eosin (H&E) staining photographs (a: stratum corneum, b: epithelium,
c: connective tissue, d: maxillae) (Scale bar: 500 μm). (B) Mean values of maximum palatal wound width calculated from the HE-stained sections.
*indicates a significant difference in palatal wound width of DMOG-treated groups compared to that of the untreated control groups (P < 0.05)
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its high viscosity and excellent biocompatibility; less
cytotoxic and no inflammatory or allergic effects. How-
ever, the oral environment is extremely dynamic. Food,
saliva, and drinking water can quickly remove topically
applied hydrogels. In the present study, the porous
structure of the hyaluronic acid hydrogel was not ob-
served on the H-E stained sections, indicating that hya-
luronic acid and incorporated DMOG had been washed
away from the wound area before sacrifice on day 7.
Therefore, it was not possible to estimate a valid amount
of DMOG for wound healing. In this study, DMOG was
applied at 0.5 and 1 mg/ml. A modest but statistically
significant reduction in the wound area and distance oc-
curred only at 1 mg/ml (Figs. 4 and 5). A more durable
vehicle and increased concentration of DMOG could
further accelerate healing of the palatal wound. However,
the results of this study did demonstrate that HIF-1α is
a potent target of wound healing in oral tissues.
Conclusions
The expression of VEGF mRNA in RP cells was enhanced
by DMOG. VEGF and HIF-1α protein expression werealso increased significantly by treatment with DMOG.
Topical application of 1 mg/ml DMOG with hyaluronic
acid ointment significantly accelerated healing of palatal
wounds in rats. These results demonstrate the usefulness
of DMOG for promotion of wound healing of oral soft
tissues.
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